| Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in … JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Blood, The Journal of the American Society of Hematology 124 (21), 330-330, 2014 | 112 | 2014 |
| Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: A randomized, phase 2, double-blind, placebo-controlled study E Price, M Bombardieri, A Kivitz, F Matzkies, O Gurtovaya, A Pechonkina, ... Rheumatology 61 (12), 4797-4808, 2022 | 27 | 2022 |
| Efficacy of Idelalisib in CLL Subpopulations Harboring Del(17p) and Other Adverse Prognostic Factors: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Trial SS Sharman J.P., Coutre S.E., Furman R.R., Cheson B.D., Pagel J.M., Hillmen ... IEHC, 2014 | 13* | 2014 |
| FRI0150 GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY A Kivitz, D Mehta, F Matzkies, A Mozaffarian, R Kunder, JADI Paolo, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 746-747, 2019 | 3 | 2019 |
| OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS DD Gladman, W Jiang, A Hertz, V Malkov, OK Yoon, M Trivedi, M Alani, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 140-140, 2020 | 1 | 2020 |
| Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with … T Munir, P Hillmen, J Sharman, S Coutre, R Furman, B Cheson, J Pagel, ... Br. J. Haematol. 169, 19-20, 2015 | 1 | 2015 |
| Filgotinib treatment leads to rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe psoriatic arthritis VC Dafna Gladman, Wendy Jiang, Angie Hertz, Vlad Malkov, Oh Kyu Yoon, Mona ... | | 2020 |
| THU0031 FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS DD Gladman, R Galien, C Jamoul, M Trivedi, N Mozaffarian, O Yoon, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 283-283, 2019 | | 2019 |
| Filgotinib Treatment Provides Rapid and Sustained Reduction of Inflammatory Biomarkers in Moderate to Severe Psoriatic Arthritis (PsA) Patients JK Dafna Gladman, Rene Galien, Corrine Jamoul, Mona Trivedi, Neelufar ... | | 2019 |
| GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients With Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study MCG Alan Kivitz, Daksha Mehta, Franziska Matzkies, Afsaneh Mozaffarian ... | | 2019 |
| GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study MCG Alan Kivitz, Daksha Mehta, Franziska Matzkies, Rebecca Kunder, Julie A ... ACR/ARHP, 2018 | | 2018 |
| A phase 1 pharmacodynamic study of the JAK1/2 inhibitor Momelotinib reveals prolonged biological responses due to attenuation of total STAT3 levels in whole blood A Kwei,K., Johnson,A., Jiang,W., Saddier-Axe,D., Wang,H., Vimal,M., Xin,Y ... ASCO, 2015 | | 2015 |
| EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND … P Ghia, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Haematologica 99, 56-58, 2014 | | 2014 |
